6 May 2020 

Scientists at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy have claimed that a vaccine candidate could neutralise coronavirus within human cells. According to findings from the tests conducted at Spallanzani Hospital in Rome, the vaccine had generated antibodies in mice that also work on human cells.

Gilead Sciences is in discussions with chemical and pharmaceutical manufacturing companies for the production of its experiment antiviral drug remdesivir, which is being tested as a potential Covid-19 treatment, for global supply through at least 2022. The company aims to form a consortium of manufacturing partners in an effort to maximise supply worldwide.

Novartis’s partner Incyte is set to launch a second Phase III clinical trial in the US to assess Jakafi (ruxolitinib) to treat Covid-19 patients on mechanical ventilation with acute respiratory distress syndrome (ARDS). The first Phase III trial of the drug, which is investigating if the drug can treat Covid-19-related cytokine storm, is sponsored by Incyte in the US and by Novartis outside of the US.

Regeneron Pharmaceuticals has said that its investigational antibody therapy for Covid-19 could be available for dosing by the end of August this year. The company advanced its lead neutralising antibodies into pre-clinical and clinical-scale cell production lines last month. The company is also working to rapidly scale-up manufacturing.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.